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LETTER TO THE EDITOR Open Access
Discovery of KIRREL as a biomarker for
prognostic stratification of patients with
thin melanoma
Sebastian Lundgren1, Helena Fagerström-Vahman1, Cheng Zhang2, Liv Ben-Dror1, Adil Mardinoglu2,
Mathias Uhlen2, Björn Nodin1 and Karin Jirström1*
Abstract
There is a great unmet clinical need to identify patients with thin primary cutaneous melanomas (T1, Breslow
thickness ≤ 1 mm) who have a high risk for tumour recurrence and death from melanoma. Kin of IRRE-like
protein 1 (KIRREL/NEPH1) is expressed in podocytes and involved in glomerular filtration. Screening in the
Human Protein Atlas portal revealed a particularly high expression of KIRREL in melanoma, both at the mRNA
and protein levels. In this study, we followed up on these findings and examined the prognostic value of
KIRREL in a population-based cohort.
Immunohistochemical expression of KIRREL was examined in tissue microarrays with a subset of primary
tumours and paired lymph node metastases from an original cohort of 268 incident cases of melanoma in
the Malmö Diet and Cancer study. KIRREL mRNA expression was examined in 103 melanoma cases in The
Cancer Genome Atlas (TCGA).
Membranous/cytoplasmic expression of KIRREL was detected in 158/185 (85.4%) primary tumours and 18/19
(94.7%) metastases. High expression of KIRREL was significantly associated with several unfavourable
clinicopathological factors.
High KIRREL protein expression was an independent factor of reduced recurrence free and melanoma specific
survival, particularly in thin melanomas, even outperforming absolute thickness and ulceration (HR = 30.85; 95%
CI 1.54–616.36 and HR = 6.32 95% CI 1.19–33.65). High mRNA levels of KIRREL were not significantly associated
with survival in TCGA.
In conclusion, KIRREL is not only a novel potential diagnostic marker for melanoma, but may also be a useful
prognostic biomarker for improved stratification of patients with thin melanoma. These findings may be of
high clinical relevance and therefore merit further validation.
Keywords: Melanoma, KIRREL, NEPH1, Prognosis
Cutaneous melanoma is the most aggressive and deadli-
est form of skin cancer with a rising incidence globally
[1]. Kin of IRRE protein (KIRREL) is a member of a
podocin binding protein family, which primary physio-
logical role is in the renal glomeruli where it safeguards
selective ultrafiltration [2]. As of yet, research regarding
the expression and role of KIRREL in cancer has been
sparse. A recent study demonstrated that high expression
of KIRREL is associated with unfavorable clinicopathologi-
cal factors and poor prognosis in gastric cancer [3], and
KIRREL has also been implicated in the carcinogenesis of
pancreatic cancer [4]. We conducted a screening of
mRNA and protein levels of KIRREL across several can-
cers and normal tissues in the Human Protein Atlas
(HPA) portal (www.proteinatlas.org) [5], which revealed a
particularly high expression in melanoma. The aim of this
study was therefore to further investigate the expres-
sion, clinicopathological correlates and prognostic im-
pact of KIRREL in melanoma, both at the protein and
mRNA levels.
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Fig. 1 (See legend on next page.)
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Results and discussion
mRNA and protein expression of KIRREL in various types
of cancers in the HPA are shown in Fig. 1 a, b. KIRREL
expression was further examined by immunohistochemi-
cal analysis of 226 cases of incident melanoma in the
population-based cohort Malmö Diet and Cancer study,
from which tissue microarrays had been constructed as
previously described (Additional file 1) [6].
Sample immunohistochemical images of KIRREL stain-
ing are shown in Fig. 1c. Digital images of KIRREL expres-
sion in 12 cases of melanoma are also shown in the HPA:
https://www.proteinatlas.org/ENSG00000183853-KIR-
REL/pathology/tissue/melanoma.
Membranous and cytoplasmic KIRREL expression was
detected in 158/185 (85.4%) of evaluable primary tu-
mours and in 18/19 (94.7%) of evaluable metastases.
Pairwise comparisons between mean expression of KIR-
REL in primary tumours and metastases revealed a
higher expression in the latter, however this difference
was not significant (p = 0.17).
The associations of KIRREL expression with clinico-
pathological factors are detailed in Additional file 2, and
significant associations are visualized in Fig. 2. High ex-
pression of KIRREL was significantly associated with
several unfavourable clinicopathological traits, including
high Clark level and Breslow stage, ulceration, clinical
stage, and high mitotic count. These findings are in line
with a recent study on gastric cancer that demonstrated
that KIRREL expression is associated with several ad-
verse clinicopathological factors [3, 7].
Next we examined the impact of immunohisto-
chemical KIRREL expression on patient outcome.
After a median follow-up of 11.8 years (range 0.6–
24.8), 113 (50%) of patients had died, 36 (31.8%) of
whom from melanoma, and recurrent disease was de-
noted in 50 (22.1%) cases. As shown in Fig. 3, high
KIRREL expression was a significantly associated with
reduced melanoma-specific survival (MSS) (p = 0.017),
and a trend, however non-significant, towards a
shorter recurrence free survival (RFS) (p = 0.071).
These associations were confirmed in univariable Cox
regression analysis (Hazard ratio [HR] = 1.69 95%
Confidence interval [CI] 0.95–2.99 and HR = 2.23 95%
CI 1.13–4.00, respectively), but did not remain signifi-
cant in multivariable analysis (data not shown).
In thin melanomas (Breslow thickness ≤ 1 mm) high
protein expression of KIRREL was significantly associ-
ated with both poor RFS and reduced MSS (p = 0.004
and p = 0.007, respectively) (Fig. 3). As shown in
Additional file 3, these associations were confirmed in
univariable Cox regression analysis and remained sig-
nificant in multivariable analysis (HR = 30.8; 95% CI
1.34–616, HR = 6.32 95% CI1.19–33.65 respectively),
even outperforming well-established prognostic factors
such as absolute thickness in millimetre and presence
of ulceration.
Thin melanomas already make up 70% of all newly
diagnosed melanomas [8], a number that may in-
crease due to efforts for earlier diagnosis, and al-
though they can collectively be regarded as having a
good prognosis, some tumours will metastasize and
lead to death. Current clinical protocols still lack reli-
able biomarkers for stratification of patients with thin
melanoma having high or low risk for recurrence, and
the findings in this paper indicate that KIRREL might
valuable in this regard.
In order to validate the findings at the protein level,
data on mRNA expression of KIRREL was retrieved
from 103 melanoma cases in TCGA. As only two
cases had matched samples from the primary tumour
and metastasis, no meaningful comparison could be
performed. There was no significant association be-
tween KIRREL expression and clinical stage (data not
shown) and information on other clinicopathological
factors was not available.
KIRREL expression was not prognostic at the mRNA
level (Additional file 4), and as only 3 cases were stage I,
no subgroup analysis could be carried out for thin
melanoma.
Conclusions
This is the first study to describe the expression of
KIRREL at the protein and mRNA levels in cutaneous
melanoma. The results demonstrate a particularly
high expression of KIRREL in melanoma compared to
other types of solid cancer, in both primary tumours
and metastases, hence highlighting its potential as a
novel diagnostic adjunct. Moreover, KIRREL may also
prove to be a useful biomarker for improved prognos-
tic stratification of thin melanoma, an entity for
which there is great unmet need for improved risk
stratification. Further research into the role of KIR-
REL in the pathogenesis and progression of melan-
oma, and validatory studies regarding its clinical
impact, are warranted.
(See figure on previous page.)
Fig. 1 Overview of KIRREL expression at the mRNA and protein levels in different cancer types and sample images of immunohistochemical staining
in melanoma. a KIRREL mRNA expression overview and (b) KIRREL protein expression summary across several cancer types. c Immunohistochemical
images from melanoma cases in the Malmö Diet and Cancer study, exemplifying tumors with 1) negative, 2) intermediate, and 3) high expression
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Fig. 2 Distribution of KIRREL expression in relation to clinicopathological factors. Box plots visualizing the distribution of the full KIRREL score in
relation to clinicopathological factors. Only significant p-values are shown. Error bars indicate 95% confidence interval
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Fig. 3 Kaplan-Meier estimates illustrating differences in clinical outcome stratified by KIRREL expression. a Recurrence free survival in the entire
cohort. b Melanoma specific survival in the entire cohort. c Recurrence free survival in thin melanomas only. d Melanoma specific survival in thin
melanomas only
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Additional file 1: Materials and Methods. (DOCX 19 kb)
Additional file 2: Associations of KIRREL protein expression with
clinicopathological factors in the entire cohort. (DOCX 22 kb)
Additional file 3: Cox regression analysis of hazard ratios for A) recurrence
and B) death from melanoma in thin melanoma. (DOCX 23 kb)
Additional file 4: Kaplan-Meier curve illustrating overall survival
according to high and low mRNA expression (median cutoff) in TCGA
dataset. (PDF 45 kb)
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